Shares of Relay Therapeutics (RLAY) plunged 5.42% in pre-market trading on Tuesday, following a significant price target cut by Leerink Partners. The move reflects growing concerns about the company's near-term prospects in the competitive healthcare sector.

Leerink Partners, a well-respected healthcare investment bank, reduced its price target for Relay Therapeutics from $14 to $12, representing a 14.3% decrease. This adjustment suggests that analysts at Leerink have become more cautious about the company's potential for growth or profitability in the coming months. The lowered target price often leads investors to reassess their positions, potentially triggering a sell-off.

Adding to the complexity of Relay Therapeutics' market position, recent reports indicate mixed opinions among analysts covering the healthcare sector. This divergence in expert views underscores the challenges and uncertainties facing the company, which specializes in precision medicines. As investors digest these conflicting signals, the stock's volatility may persist in the short term, with market participants closely watching for any further developments or guidance from the company.